← Leaderboards
Trever G Bivona
University Of California, San Francisco
$22,714,857
Attributed
$32,733,512
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,264,278 · 15
By mechanism
U54$15,327,078 · 4
R01$13,216,238 · 6
U01$9,130,560 · 2
K12$2,581,772 · 1
DP2$2,348,750 · 1
K08$659,880 · 1
Top collaborators
- Sourav Bandyopadhyay9 shared
- Michael T Mcmanus9 shared
- Bo Huang6 shared
- Jonathan S. Weissman6 shared
- Emily K Bergsland5 shared
- Calvin J Kuo5 shared
- Jack Roth5 shared
- Xiaokun Shu2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Bo Huang$11,811,437
- Ross Okimoto$3,105,765
- Jason G. Cyster$29,153,268
- Sourav Bandyopadhyay$8,349,973
- Xiaokun Shu$12,879,545
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceMalignant NeoplasmsMolecularInnovationMalignant Neoplasm Of LungResponseTumorGeneticPathway InteractionsCancer EtiologySpecimenMutantCellsCancer PatientDrug ResistanceCancer CellSignal TransductionGrowthSuccessEpidermal Growth Factor ReceptorNeoplastic CellAreaNon-Small-Cell Lung CarcinomaBase
Grant awards (76)
BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)$1,079,739
U54 · FY2025 · CA · contact PI
Bay Area Cancer Target Discovery and Development$992,465
U01 · FY2025 · CA
Dissecting the role and mechanism of EML4-ALK condensates in oncogenic signaling and tumor growth$670,212
R01 · FY2025 · CA · contact PI
UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology$643,767
K12 · FY2025 · CA
Characterization of YAP as a rational companion target in lung cancer$383,563
R01 · FY2025 · CA · contact PI
Clinical specimen tumor-TME acquired resistance$311,509
U54 · FY2025 · CA · contact PI
BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)$1,030,386
U54 · FY2024 · CA · contact PI
Bay Area Cancer Target Discovery and Development$942,785
U01 · FY2024 · CA
UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology$705,060
K12 · FY2024 · CA
Dissecting the role and mechanism of EML4-ALK condensates in oncogenic signaling and tumor growth$636,702
R01 · FY2024 · CA · contact PI
Stress responses drive resistance and shape tumor evolution in EGFR mutant lung cancer$478,245
R01 · FY2024 · CA · contact PI
Characterization of YAP as a rational companion target in lung cancer$364,384
R01 · FY2024 · CA · contact PI
Clinical specimen tumor-TME acquired resistance$295,923
U54 · FY2024 · CA · contact PI
BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)$1,067,511
U54 · FY2023 · CA · contact PI
Bay Area Cancer Target Discovery and Development$976,551
U01 · FY2023 · CA
UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology$757,279
K12 · FY2023 · CA
Dissecting the role and mechanism of EML4-ALK condensates in oncogenic signaling and tumor growth$670,214
R01 · FY2023 · CA · contact PI
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules$448,648
R01 · FY2023 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$375,891
R01 · FY2023 · CA · contact PI
Characterization of YAP as a rational companion target in lung cancer$375,891
R01 · FY2023 · CA · contact PI
Clinical specimen tumor-TME acquired resistance$305,261
U54 · FY2023 · CA · contact PI
ARTNet NOSI Supplement$80,750
U54 · FY2023 · CA · contact PI
Clinical specimen tumor-TME acquired resistance$80,750
U54 · FY2023 · CA · contact PI
BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)$1,119,180
U54 · FY2022 · CA · contact PI
Bay Area Cancer Target Discovery and Development$969,145
U01 · FY2022 · CA
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules$448,646
R01 · FY2022 · CA · contact PI
UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology$422,289
K12 · FY2022 · CA
Characterization of YAP as a rational companion target in lung cancer$383,563
R01 · FY2022 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$375,891
R01 · FY2022 · CA · contact PI
Clinical specimen tumor-TME acquired resistance$357,227
U54 · FY2022 · CA · contact PI
Bay Area Team Against Resistance$1,149,528
U54 · FY2021 · CA · contact PI
The Cancer Target Discovery and Development Network at UCSF$1,026,728
U01 · FY2021 · CA
UCSF Project 1$524,054
U54 · FY2021 · CA · contact PI
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules$457,804
R01 · FY2021 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$383,563
R01 · FY2021 · CA · contact PI
Optimizing biologically-based rational polytherapy in ALK+ lung cancer$362,569
R01 · FY2021 · CA · contact PI
Characterization of YAP as a rational companion target in lung cancer$362,569
R01 · FY2021 · CA · contact PI
Admin Core$108,905
U54 · FY2021 · CA · contact PI
UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology$53,377
K12 · FY2021 · CA
Bay Area Team Against Resistance$1,185,025
U54 · FY2020 · CA · contact PI
The Cancer Target Discovery and Development Network at UCSF$1,029,182
U01 · FY2020 · CA
UCSF Project 1$537,768
U54 · FY2020 · CA · contact PI
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules$457,804
R01 · FY2020 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$382,573
R01 · FY2020 · CA · contact PI
Characterization of YAP as a rational companion target in lung cancer$362,569
R01 · FY2020 · CA · contact PI
Optimizing biologically-based rational polytherapy in ALK+ lung cancer$362,569
R01 · FY2020 · CA · contact PI
Admin Core$114,372
U54 · FY2020 · CA · contact PI
Bay Area Team Against Resistance$1,277,605
U54 · FY2019 · CA · contact PI
The Cancer Target Discovery and Development Network at UCSF$1,000,618
U01 · FY2019 · CA
UCSF Project 1$585,896
U54 · FY2019 · CA · contact PI
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules$454,969
R01 · FY2019 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$380,693
R01 · FY2019 · CA · contact PI
Optimizing biologically-based rational polytherapy in ALK+ lung cancer$351,691
R01 · FY2019 · CA · contact PI
Characterization of YAP as a rational companion target in lung cancer$351,691
R01 · FY2019 · CA · contact PI
Admin Core$124,974
U54 · FY2019 · CA · contact PI
The Cancer Target Discovery and Development Network at UCSF$1,158,875
U01 · FY2018 · CA
Optimizing biologically-based rational polytherapy in ALK+ lung cancer$362,569
R01 · FY2018 · CA · contact PI
Characterization of YAP as a rational companion target in lung cancer$362,569
R01 · FY2018 · CA · contact PI
Admin Core$140,000
U54 · FY2018 · CA · contact PI
Bay Area Team Against Resistance$140,000
U54 · FY2018 · CA · contact PI
Bay Area Team Against Resistance$2,401,042
U54 · FY2017 · CA · contact PI
UCSF Project 1$1,085,090
U54 · FY2017 · CA · contact PI
The Cancer Target Discovery and Development Network at UCSF$1,034,211
U01 · FY2017 · CA
Characterization of YAP as a rational companion target in lung cancer$362,569
R01 · FY2017 · CA · contact PI
Optimizing biologically-based rational polytherapy in ALK+ lung cancer$362,569
R01 · FY2017 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$342,701
R01 · FY2017 · CA · contact PI
Admin Core$224,583
U54 · FY2017 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$342,701
R01 · FY2016 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$300,075
R01 · FY2015 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$246,817
R01 · FY2014 · CA · contact PI
Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFR$154,440
K08 · FY2014 · CA · contact PI
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment$250,754
R01 · FY2013 · CA · contact PI
Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFR$168,480
K08 · FY2013 · CA · contact PI
Discovery of Rational Companion Therapeutic Targets to Optimize Cancer Treatment$2,348,750
DP2 · FY2012 · CA · contact PI
Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFR$168,480
K08 · FY2012 · CA · contact PI
Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFR$168,480
K08 · FY2011 · CA · contact PI